Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.58 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | MIF | P14174 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535230 | 1.00 | ESR1 (0.58) | ESR1ESR2PPARAMIFPTGS2 | |
| SCHEMBL4821206 | 0.89 | CA1 (0.56) | ESR1ESR2PPARAMIFPTGS2 | |
| SCHEMBL6419166 | 0.89 | PPARA (0.54) | ESR1ESR2PPARAPTGS2PPARG | |
| SCHEMBL977514 | 0.89 | PPARA (0.54) | ESR1ESR2PPARAPTGS2PPARG | |
| SCHEMBL977513 | 0.89 | PPARA (0.54) | ESR1ESR2PPARAPTGS2PPARG | |
| SCHEMBL7815559 | 0.88 | ESR1 (0.55) | ESR1ESR2PPARAMIFPTGS2 | |
| SCHEMBL1865433 | 0.86 | PPARA (0.48) | ESR1ESR2PPARAPPARGPPARD | |
| SCHEMBL1750767 | 0.86 | PPARA (0.51) | ESR1ESR2PPARAPPARGPPARD | |
| SCHEMBL3536105 | 0.86 | PPARA (0.48) | ESR1ESR2PPARAPPARGPPARD | |
| SCHEMBL1750768 | 0.86 | PPARA (0.51) | ESR1ESR2PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550719-B2 | Process for the preparation of 3-aryl-2-hydroxy propanoic acid compounds | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-01-24 | — | — | US | disclosed |
| US-20160102042-A1 | A PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID COMPOUNDS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-04-14 | — | — | US | disclosed |
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | disclosed |
| EP-1578716-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| EP-1517882-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | disclosed |
| WO-2004056740-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004000789-A9 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004000789-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| US-6559335-B2 | Benzylation; concurrent etherification, esterification | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-05-06 | — | — | US | disclosed |
| US-20020177726-A1 | Process for the preparation of 3-aryl-2-hydroxy propanoic acid | DR. REDDY'S RESEARCH FOUNDATION | 2002-11-28 | — | — | US | disclosed |
| WO-2002024625-A2 | PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259950-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | ESR1 1589/4885ESR2 491/4885PPARA 2/4885 |
| US-20160102042-A1 | A PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID COMPOUNDS | P4HA1, HCAR1, HPD | ESR1 2872/4885ESR2 2877/4885PPARA 206/4885 |
| US-20020177726-A1 | Process for the preparation of 3-aryl-2-hydroxy propanoic acid | HPD, HAO1, HAAO | ESR1 4342/4885ESR2 3747/4885PPARA 265/4885 |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | ESR1 136/4885ESR2 52/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.